| Trastuzumab deruxtecan in previously treated HER2-positive breast cancer S Modi, C Saura, T Yamashita, YH Park, SB Kim, K Tamura, F Andre, ... New England Journal of Medicine 382 (7), 610-621, 2020 | 1625 | 2020 |
| Trastuzumab Deruxtecan in HER2-Mutant Non–Small-Cell Lung Cancer BT Li, EF Smit, Y Goto, K Nakagawa, H Udagawa, J Mazières, ... New England Journal of Medicine 386 (3), 241-251, 2022 | 624 | 2022 |
| Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low–expressing advanced breast cancer: results from a phase Ib study S Modi, H Park, RK Murthy, H Iwata, K Tamura, J Tsurutani, ... Journal of Clinical Oncology 38 (17), 1887-1896, 2020 | 615 | 2020 |
| Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study K Tamura, J Tsurutani, S Takahashi, H Iwata, IE Krop, C Redfern, ... The Lancet Oncology 20 (6), 816-826, 2019 | 340 | 2019 |
| Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial S Siena, M Di Bartolomeo, K Raghav, T Masuishi, F Loupakis, ... The Lancet Oncology 22 (6), 779-789, 2021 | 296 | 2021 |
| Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study K Shitara, H Iwata, S Takahashi, K Tamura, H Park, S Modi, J Tsurutani, ... The Lancet Oncology 20 (6), 827-836, 2019 | 199 | 2019 |
| Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): Interim results of DESTINY-Lung01. EF Smit, K Nakagawa, M Nagasaka, E Felip, Y Goto, BT Li, JM Pacheco, ... Journal of Clinical Oncology 38 (15_suppl), 9504-9504, 2020 | 137 | 2020 |
| Measuring the quality of life of people at the end of life: The McGill Quality of Life Questionnaire–Revised SR Cohen, R Sawatzky, LB Russell, J Shahidi, DK Heyland, ... Palliative medicine 31 (2), 120-129, 2017 | 135 | 2017 |
| Not telling the truth: circumstances leading to concealment of diagnosis and prognosis from cancer patients J Shahidi European journal of cancer care 19 (5), 589-593, 2010 | 127 | 2010 |
| Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing solid tumors: Long-term results of a large phase 1 study with multiple expansion cohorts. H Iwata, K Tamura, T Doi, J Tsurutani, S Modi, H Park, IE Krop, Y Sagara, ... Journal of Clinical Oncology 36 (15_suppl), 2501-2501, 2018 | 99 | 2018 |
| Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine–cisplatin plus necitumumab … L Paz-Ares, MA Socinski, J Shahidi, RR Hozak, V Soldatenkova, R Kurek, ... Annals of Oncology 27 (8), 1573-1579, 2016 | 80 | 2016 |
| A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01. S Siena, M Di Bartolomeo, KPS Raghav, T Masuishi, F Loupakis, ... Journal of Clinical Oncology 38 (15_suppl), 4000-4000, 2020 | 73 | 2020 |
| OA04. 05 trastuzumab deruxtecan in HER2-overexpressing metastatic non-small cell lung cancer: interim results of DESTINY-Lung01 K Nakagawa, M Nagasaka, E Felip, J Pacheco, C Baik, Y Goto, A Saltos, ... Journal of Thoracic Oncology 16 (3), S109-S110, 2021 | 71 | 2021 |
| More comprehensively measuring quality of life in life-threatening illness: the McGill quality of life questionnaire–expanded SR Cohen, LB Russell, A Leis, J Shahidi, P Porterfield, DR Kuhl, ... BMC palliative care 18, 1-11, 2019 | 43 | 2019 |
| Abstract PD3-06: Updated results from DESTINY-breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd) in HER2 positive metastatic breast cancer S Modi, C Saura, T Yamashita, YH Park, SB Kim, K Tamura, F Andre, ... Cancer research 81 (4_Supplement), PD3-06-PD3-06, 2021 | 36 | 2021 |
| Abstract P6-17-06: Characterization, monitoring and management of interstitial lung disease in patients with metastatic breast cancer: Analysis of data available from multiple … CA Powell, DR Camidge, A Gemma, M Kusumoto, T Baba, K Kuwano, ... Cancer Research 79 (4_Supplement), P6-17-06-P6-17-06, 2019 | 32 | 2019 |
| McGill Quality of Life Questionnaire: reliability and validity of the Persian version in Iranian patients with advanced cancer J Shahidi, R Khodabakhshi, MR Gohari, H Yahyazadeh, N Shahidi Journal of palliative medicine 11 (4), 621-626, 2008 | 30 | 2008 |
| Exposure‐response relationships in patients with HER2‐positive metastatic breast cancer and other solid tumors treated with trastuzumab deruxtecan O Yin, H Iwata, CC Lin, K Tamura, J Watanabe, R Wada, H Kastrissios, ... Clinical Pharmacology & Therapeutics 110 (4), 986-996, 2021 | 27 | 2021 |
| Truth-telling to cancer patients from relatives’ point of view: a multi-centre study in Iran J Shahidi, A Taghizadeh-Kermani, S Yahyazadeh, R Khodabakhshi, ... Austral-Asian Journal of Cancer 6 (4), 213-17, 2007 | 25 | 2007 |
| Reimagining patient-centric cancer clinical trials: a multi-stakeholder international coalition BT Li, B Daly, M Gospodarowicz, MM Bertagnolli, OW Brawley, ... Nature medicine 28 (4), 620-626, 2022 | 24 | 2022 |
